Mitochondrial dysfunction induced by sertraline, an antidepressant agent

Toxicological Sciences

Volumn 127, Issue 2, 2012, Pages 582-591

  Li, Yan ^a   Couch, Letha ^a   Higuchi, Masahiro ^b   Fang, Jia Long ^a   Guo, Lei ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Isolated liver mitochondria; Liver toxicity; Mitochondrial dysfunction; Rat primary hepatocytes; Sertraline

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; BONGKREKIC ACID; LACTATE DEHYDROGENASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SERTRALINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; LIVER CELL; MALE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; RAT; TOXIC HEPATITIS;

RATTUS;

EID: 84861468623     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs100     Document Type: Article

References (55)

1. Al-Nasser, I., and Crompton, M. (1986). The reversible Ca2+-induced permeabilization of rat liver mitochondria. Biochem. J. 239, 19.
2. Atlante, A., Bobba, A., De Bari, L., Fontana, F., Calissano, P., Marra, E., and Passarella, S. (2006). Caspase dependent alteration of the ADP/ATP translocator triggers the mitochondrial permeability transition which is not required for the low potassium dependent apoptosis of cerebellar granule cells. J. Neurochem. 97, 1166-1181.
3. Atlante, A., de Bari, L., Bobba, A., Marra, E., Calissano, P., and Passarella, S. (2003). Cytochrome c, released from cerebellar granule cells undergoing apoptosis or excytotoxic death, can generate protonmotive force and drive ATP synthesis in isolated mitochondria. J. Neurochem. 86, 591-604.
4. Biour, M., Poupon, R., Grange, J. D., Chazouilleres, O., Levy, V. G., Bodin, F., and Cheymol, G. (1992). Hépatotoxicité des médicaments: Mise a' jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol. Clin. Biol. 16, 64-88.
5. Broekemeier, K. M., Dempsey, M. E., and Pfeiffer, D. R. (1989). Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem. 264, 7826-7830.
6. Collados, V., Hallal, H., and Andrade, R. J. (2010). Sertraline hepatotoxicity: Report of a case and review of the literature. Dig. Dis. Sci. 55, 1806-1807.
7. Collados Arroyo, V., Plaza Aniorte, J., Hallal, H., and Pérez Cuadrado, E. (2008). Hepatotoxicidad asociada a sertralina. Farm. Hosp. 32, 60-61.
8. Connern, C. P., and Halestrap, A. P. (1994). Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem. J. 302(Pt 2), 321-324.
9. Crompton, M. (1999). The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341(Pt 2), 233-249.
10. Davies, T. S., and Kluwe, W. M. (1998). Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem. Toxicol. 21, 521-537.
11. DeVane, C. L., Liston, H. L., and Markowitz, J. S. (2002). Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41, 1247-1266.
12. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., and Will, Y. (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 103, 335-345.
13. Dykens, J. A., Marroquin, L. D., and Will, Y. (2007). Strategies to reduce latestage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7, 161-175.
14. Fartoux-Heymann, L., Hezode, C., Zafrani, E. S., Dhumeaux, D., and Mallat, A. (2001). Acute fatal hepatitis related to sertraline. J. Hepatol. 35, 683-684.
15. Fiore, C., Trezeguet, V., Le Saux, A., Roux, P., Schwimmer, C., Dianoux, A. C., Noel, F., Lauquin, G. J., Brandolin, G., and Vignais, P. V. (1998). The mitochondrial ADP/ATP carrier: Structural, physiological and pathological aspects. Biochimie 80, 137-150.
16. Frezza, C., Cipolat, S., and Scorrano, L. (2007). Organelle isolation: Functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc. 2, 287-295.
17. Galán Navarro, J. (2001). Hepatitis aguda colestásica probablemente causada por sertralina. Rev. Esp. Enferm. Dig. 93, 822.
18. Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J. L., Green, B., Deng, H., Kaput, J., and Ning, B. (2011). Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39, 528-538.
19. Guo, L., Fang, H., Collins, J., Fan, X., Dial, S., Wong, A., Mehta, K., Blann, E., Shi, L., and Tong, W. (2006a). Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor a agonists. BMC Bioinformatics 7, S18.
20. Guo, L., Zhang, L., Sun, Y., Muskhelishvili, L., Blann, E., Dial, S., Shi, L., Schroth, G., and Dragan, Y. P. (2006b). Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 10, 349-360.
21. Hautekeete, M. L., Colle, I., van Vlierberghe, H., and Elewaut, A. (1998). Symptomatic liver injury probably related to sertraline. Gastroenterol. Clin. Biol. 22, 364-365.
22. Haworth, R. A., and Hunter, D. R. (1979). The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch. Biochem. Biophys. 195, 460-467.
23. Hogeboom, G. H., Schneider, W. C., and Pallade, G. E. (1948). Cytochemical studies of mammalian tissues: I. Isolation of intact mitochondria from rat liver; some biochemical properties of mitochondria and submicroscopic particulate material. J. Biol. Chem. 172, 619.
24. Hunter, D. R., and Haworth, R. A. (1979). The Ca2+-induced membrane transition in mitochondria. III. Transitional Ca2+ release. Arch. Biochem. Biophys. 195, 468-477.
25. Imai, H., Koumura, T., Nakajima, R., Nomura, K., and Nakagawa, Y. (2003). Protection from inactivation of the adenine nucleotide translocator during hypoglycaemia-induced apoptosis by mitochondrial phospholipid hydroperoxide glutathione peroxidase. Biochem. J. 371, 799-809.
26. Kim, K. Y., Hwang, W., and Narendran, R. (1999). Acute liver damage possibly related to sertraline and venlafaxine ingestion. Ann. Pharmacother. 33, 381-382.
27. Kirby, D., Thorburn, D., Turnbull, D., and Taylor, R. (2007). Biochemical assays of respiratory chain complex activity. In Methods in Cell Biology (L. Wilson and P. Matsudaira, Eds.), pp. 93-119. Academic Press, San Diego, CA.
28. Klingenberg, M., and Buchholz, M. (1973). On the mechanism of bongkrekate effect on the mitochondrial adenine-nucleotide carrier as studied through the binding of ADP. Eur. J. Biochem. 38, 346-358.
29. Korzeniewski, C., and Callewaert, D. M. (1983). An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64, 313-320.
30. Kreamer, B. L., Staecker, J. L., Sawada, N., Sattler, G. L., Hsia, M. T. S., and Pitot, H. C. (1986). Use of a low-speed, iso-density Percoll centrifugation method to increase the viability of isolated rat hepatocyte preparations. In Vitro Cell. Dev. Biol. Plant 22, 201-211.
31. Kristensen, S. R. (1989). A critical appraisal of the association between energy charge and cell damage. Biochim. Biophys. Acta Mol. Cell Res. 1012, 272-278
32. Kroemer, G., Galluzzi, L., and Brenner, C. (2007). Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163
33. Labbe, G., Pessayre, D., and Fromenty, B. (2008). Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 22, 335-353.
34. Lee, W. M. (2003). Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
35. Lin, D. T., and Lechleiter, J. D. (2002). Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. J. Biol. Chem. 277, 31134-31141.
36. Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., and Will, Y. (2007). Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539-547.
37. Martínez Matos, Y. (2002). Mujer de mediana edad con prurito y patrón analítico de colestasis aguda. SEMERGEN 28, 105-107.
38. Masubuchi, Y., Kano, S., and Horie, T. (2006). Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222, 233-239.
39. Masubuchi, Y., Yamada, S., and Horie, T. (1999). Diphenylamine as an important structure of nonsteroidal anti-inflammatory drugs to uncouple mitochondrial oxidative phosphorylation. Biochem. Pharmacol. 58, 861-865.
40. Ong, M. M., Latchoumycandane, C., and Boelsterli, U. A. (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97, 205-213.
41. Persky, S., and Reinus, J. F. (2003). Sertraline hepatotoxicity: A case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig. Dis. Sci. 48, 939-944.
42. Rossignol, R., Letellier, T., Malgat, M., Rocher, C., and Mazat, J. P. (2000). Tissue variation in the control of oxidative phosphorylation: Implication for mitochondrial diseases. Biochem. J. 347(Pt 1), 45-53.
43. Saletu, B., Grunberger, J., and Linzmayer, L. (1986). On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine. J. Neural Transm. 67, 241-266.
44. Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., and Giardina, B. (2007). The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic. Am. J. Physiol. Cell Physiol. 293, C12-C21.
45. Seglen, P. O. (1976). Preparation of isolated rat liver cells. Methods Cell Biol. 13, 29-83.
46. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002). Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69, 131-138.
47. Tsujimoto, Y., Nakagawa, T., and Shimizu, S. (2006). Mitochondrial membrane permeability transition and cell death. Biochim. Biophys. Acta 1757, 1297-1300.
48. Vernetti, L., Irwin, W., Giuliano, K. A., Gough, A., Johnston, K., and Taylor, D. (2008). Cellular systems biology applied to preclinical safety testing: A case study of CellCiphrTM profiling. In Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools (S. Ekins and J. J. Xu, Eds.), pp. 53-73. John Wiley & Sons, Inc, Hoboken, NJ.
49. Verrico, M. M., Nace, D. A., and Towers, A. L. (2000). Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J. Am. Geriatr. Soc. 48, 1659-1663.
50. Wanders, R. J., Groen, A. K., Van Roermund, C. W., and Tager, J. M. (1984). Factors determining the relative contribution of the adenine-nucleotide translocator and the ADP-regenerating system to the control of oxidative phosphorylation in isolated rat-liver mitochondria. Eur. J. Biochem. 142, 417-424.
51. Wang, J. H., Liu, Z. Q., Wang, W., Chen, X. P., Shu, Y., He, N., and Zhou, H. H. (2001). Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther. 70, 42-47.
52. Warrington, S. J. (1991). Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 6(Suppl. 2), 11-21.
53. Watkins, P. B., and Whitcomb, R. W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338, 916-917.
54. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.
55. Zoloft (1997). Roering Division of Pfizer, Inc. Zoloft (Sertraline Hydrochloride) Package Insert, New York, NY.